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Guidelines and medication
compliance
To the Editor: ‘A clinical update from Kidney Disease:
Improving Global Outcomes (KDIGO)’ was reported by
Herzog CA et al.1 emphasizing the control of serum calcium
and phosphate concentrations in reducing vascular calci-
ﬁcation. Despite the availability of guidelines, medication
compliance may not be optimal (sometimes because of
inadequate instructions given to patients).
We report on a 42-year-old hemodialysis patient admit-
ted to our hospital for renal transplantation evaluation.
Plain radiography of the abdomen showed disk-shaped
pieces of high-density foreign material (Figure 1a). On
reviewing his medications, it was found that lanthanum
carbonate (1500mg daily) was being used as an oral
phosphate binder, and the radiological ﬁndings reﬂected
intact tablets in the gut. These tablets should be chewed so
that lanthanum carbonate dissociates in the upper gastro-
intestinal tract to give lanthanum ions (La3þ ) that bind
with phosphate. After proper instructions on how to
take this medication, his phosphate level decreased from
7.0 to 6.0mg/dl. Plain radiography of the abdomen showed
that the size of lanthanum carbonate tablets had been
appropriately reduced (Figure 1b). Not achieving clinical
guideline benchmarks may sometimes simply reﬂect inade-
quate instruction given to patients on how to take
medications.
1. Herzog CA, Asinger RW, Berger AK et al. Cardiovascular disease in
chronic kidney disease. A clinical update from Kidney Disease: Improving
Global Outcomes (KDIGO). Kidney Int 2011; 80: 572–586.
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Have we observed the
implications of the acute fall
in eGFR during treatment
with losartan?
To the Editor: Holtkamp et al.1 recently reported a slower
decline in renal function after an initial decrease in estimated
glomerular ﬁltration rate (eGFR) in patients assigned to angio-
tensin receptor blockers (ARBs). This was interpreted to indicate
a favorable response, and thus ARBs should be continued with
various precautions. From Table 3, however, a very robust
increase in probability of reaching study end point as a function
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Figure 1 |Abdominal plain film showed diffuse radiopaque material. (a) Abdominal plain film showed disk-shaped pieces of
high-density material. After improvement of adherence to this medication, his phosphate level decreased from 7.0 to 6.0mg/dl. (b) Plain
radiography of the abdomen showed that the lanthanum carbonate tablets had been chewed to pieces.
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of initial decrease in eGFR can be deduced (Po0.0001 by
logistic regression, using the mean change in eGFR as predictor).
This was as expected (Table 1) because a high initial eGFR
predicted a large decrease in eGFR when starting ARB
treatment, and hence more patients would show a doubling of
serum creatinine. Unfortunately, we are not told how many of
the increased end points were due to end-stage renal disease,
which would entail a low ensuing progression. Instead, a
comparison is made between patients on ARBs and on placebo
who display an initial decrease in eGFR. This is unrelated to the
question of whether ARBs should be continued, as we do not
know the reason for initial loss of eGFR in the placebo group. To
know whether we should continue ARBs in those with initial
decrease in eGFR, we would need a controlled study of such
patients who either stop or continue treatment. This hypothesis
thus generated by the study is important. Fitting straight lines,
even two or more, will help us little, but accounting for end
points might be of value. Continuing investigation2 of the
reasons for changing eGFR after ARBs is also of interest.
1. Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated
glomerular filtration rate during treatment with losartan predicts a slower
decrease in long-term renal function. Kidney Int 2011; 80: 282–287.
2. Hollenberg NK, Price DA, Fisher NDL et al. Glomerular hemodynamics and
the renin-angiotensin system in patients with type 1 diabetes mellitus.
Kidney Int 2003; 63: 172–178.
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Pre-renal success
To the Editor: Holtkamp et al.1 demonstrated that initial
declines in glomerular ﬁltration rate (GFR) resulting from
renin–angiotensin system inhibition (RASI) are commonly
associated with improved long-term renal function. The
underlying physiologic principles have been well described
and the initial studies upon which this review was based
are over 10 years old,2–4 but the concept remains poorly
understood by the medical community. Too often, internists
(and even nephrologists) diagnose the initial decline in GFR
following RASI as ‘pre-renal failure’ and reverse beneﬁcial
therapy. This problem is widespread and not limited to
RASI prescription; the same issue manifests when blood
pressure in chronic kidney disease is lowered by non-RASI
medicines.2
Although this discordance between clinical research and
clinical activity is not unique, the issue with RASIs (and blood
pressure control in general) and an initial increase in serum
creatinine has two speciﬁc characteristics:
(1) There is no well-known succinct name for this syndrome.
(2) It is not part of the commonly taught tripartite approach
to acute renal failure (‘pre-renal, renal, post-renal’).
It is hard to expect a physician to diagnose something that
does not have a name (only a long-winded description) or a
place in the standard diagnostic algorithm.
For these reasons, the term ‘pre-renal success’5 has been
suggested for the situation described by Holtkamp et al. and
others. Pre-renal success was selected for its contradistinction
to the opposing (and usual) diagnosis of ‘pre-renal failure’;
‘pre-renal’ notes that the increased serum creatinine results
from hemodynamic factors, and ‘success’ accentuates the
key point that the long-term result is something good; the
therapy should be maintained, not reversed. ‘Pre-renal
success’ is a variant of the term ‘acute renal success’ used by
Thurau and Boylan6 for the role of oliguria in acute tubular
necrosis.
I suggest that ‘pre-renal success’ be added to the standard
teaching approach to elevations in the serum creatinine
(Figure 1). When it appears that the reason for an increased
serum creatinine is hemodynamic (pre-renal), physicians
should evaluate the clinical characteristics that distinguish
pre-renal failure from pre-renal success.5
A proper name for this syndrome, and place in the standard
algorithm, should ease the current diagnostic difﬁculties.
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Figure 1 |A new diagnostic algorithm.
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